This content is from: Premium Hedge-Fund-Backed Acelyrin Makes a Strong IPO Debut In a brutal IPO environment, the biopharma company soared 30 percent in its first day of trading. By Gary Perkinson May 09, 2023
This content is from: Premium This Could Be the Next Biopharma IPO Several major hedge funds are poised to benefit if Acelyrin’s offering is successful. By Stephen Taub April 24, 2023
This content is from: Corner Office Founders Don’t Want to Sell Their Companies to You Only 16 percent of entrepreneurs want to go public and only 7 percent want to be bought by a private equity firm, according to pre-seed investor Techstars. By Hannah Zhang April 04, 2023
This content is from: Premium Ackman Treads Water in April Universal Music drags Pershing Square down, while Chipotle holds it up. By Michelle Celarier May 03, 2023
This content is from: Premium There’s New Hope for the IPO Market At least five hedge funds have benefited from two biopharma stocks that went public in February and are currently doing well. By Stephen Taub February 27, 2023
This content is from: Premium Corvex Settles With SEC Over SPAC Activities Shares of the hedge fund’s three SPAC merger partners have plummeted. By Stephen Taub April 17, 2023
